VANCOUVER, BC / ACCESSWIRE / September 7, 2017 / CVR Medical Corp. (TSX.V: CVM.V) (FRANKFURT: B3BN) (OTCQB: CRRVF) (“CVR Medical”) advisory staff member Dr. Phillip J. Bendick, PhD, has released a summarized report on data from the tertiary clinical trials for the “Carotid Stenotic Scan (CSS)” device at Thomas Jefferson University (see press release dated June 29th, 2017). His report views initial evaluations as successful, and confirms the device’s value and efficiency.
Dr. Bendick’s report reviews the most pertinent features of the data collected from these first trials. “From a clinical standpoint […] the most important point is likely that the CSS, in a statistical sense, is very specific,” he states. Nearly all of the tested patients that had carotid artery stenosis were identified without an “overread,” an important measure which allows doctors to recommend steps for further care with confidence.
“From a development standpoint […] the greatest value of this latest data is the guidance it has provided in signal analysis.” Dr. Bendick notes that CVR will derive substantial benefit from the device’s ability to separate and use only high quality sub-sonic sound during application. This ensures that background noise that could otherwise skew results will not be confused as signals for narrowing arteries with higher pressure. “Going forward, this ability […] should improve even more the accuracy of the CSS to categorize a patient’s disease severity,” he concludes.
CVR CEO Peter Bakema, speaking on its release, expressed excitement for the indications of the report. “Internally, in discussions with our engineering and scientific development teams, indications are that we expect the device to improve markedly above the 85% sensitivity level. This, coupled with the expansion of trials for a larger sample size, continues to put us in position for a successful submission to the FDA.”
For additional information on the organization, leadership, and current news please visit the company website at www.CVRMed.com.
About CVR Medical
CVR Medical is a company that is involved in an equal parts joint venture with CVR Global Inc. (the “Joint Venture”). The Joint Venture operates in the medical industry focused on the commercialization of a proprietary subsonic, infrasonic, and low frequency sound wave analysis technology and has patents to a diagnostic device designed to detect and measure carotid arterial stenosis. CVR Medical is managed by a proven technical team. CVR Medical trades on the TSX Venture Exchange under the symbol CVM.
ON BEHALF OF THE BOARD:
(signed) “Peter Bakema”
CEO, President & Director
For further information contact:
Brisco Capital Partners Corp.
Scott Koyich, President
Telephone: (403) 262-9888
This press release contains forward-looking information that involves various risks and uncertainties regarding future events related to the Joint Venture. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements and are not guarantees of future performance of the Company. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements reflect management’s current views and are based on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implied by the forward-looking statements, including: (1) a downturn in general economic conditions in North America and internationally, (2) the inherent uncertainties and speculative nature associated with commercialization of technology and the practice of medicine, (3) a change in health regulations, (4) any number of events or causes which may delay or cease commercialization and development of the Joint Venture, (5) the risk that the Company or the Joint Venture does not execute its business plan, (6) inability to retain key employees, (7) inability to finance operations and growth, and (8) other factors beyond the Company’s control. These forward-looking statements are made as of the date of this news release and, except as required by law, the Company assumes no obligation to update these forward-looking statements, or to update the reasons why actual results differed from those projected in the forward-looking statements.
THE TSX VENTURE EXCHANGE INC. HAS NEITHER APPROVED NOR DISAPPROVED THE CONTENTS OF THIS PRESS RELEASE. NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.